SOP Guide for Pharma

Quality Assurance: SOP for Internal Quality Audits in Injectable Manufacturing – V 2.0

Quality Assurance: SOP for Internal Quality Audits in Injectable Manufacturing – V 2.0

Standard Operating Procedure for Internal Quality Audits in Injectable Manufacturing


Department Quality Assurance
SOP No. SOP/QA/181/2025
Supersedes SOP/QA/181/2022
Page No. Page 1 of 13
Issue Date 24/06/2025
Effective Date 26/06/2025
Review Date 24/06/2026

1. Purpose

To define the standard procedure for planning, conducting, reporting, and following up on internal quality audits in the sterile injectable manufacturing facility. The objective is to verify compliance with GMP, internal procedures, and regulatory requirements, ensuring continuous improvement of quality

systems.

2. Scope

This SOP applies to all departments involved in sterile injectable manufacturing including production, quality control, engineering, warehouse, validation, and documentation functions. It encompasses routine, focused, and follow-up audits.

3. Responsibilities

  • Audit Coordinator (QA): Plans and schedules audits, assigns auditors, ensures report compilation and closure of audit observations.
  • Auditors: Conduct audits objectively and document findings.
  • Auditees: Provide access to information, cooperate with auditors, and implement corrective actions.
  • Department Heads: Review and respond to audit findings, ensure closure of non-conformities.

4. Accountability

The Head of Quality Assurance is accountable for ensuring that internal audits are conducted as per the approved schedule and that non-conformances are resolved in a timely and effective manner.

5. Procedure

5.1 Preparation of Audit Schedule

  1. The Audit Coordinator shall prepare an annual internal audit schedule (Annexure-1) at the beginning of the calendar year based on risk assessment and past audit findings.
  2. The schedule shall be reviewed and approved by the Head QA and communicated to all departments.

5.2 Selection and Training of Auditors

  1. Auditors shall be selected from QA and trained in auditing principles, GMP guidelines, and applicable regulatory standards.
  2. They must be independent of the areas being audited.

5.3 Conducting the Audit

  1. Auditors shall:
    • Refer to the checklist (Annexure-2) for each department/process.
    • Review documents, observe activities, and interview personnel.
    • Record all observations, including non-conformities (NC), observations (OBS), and suggestions (SUG).

5.4 Classification of Findings

  1. Non-conformities shall be categorized as:
    • Critical: Impacting product quality or patient safety.
    • Major: Deviation from SOPs, GMP, or documentation norms.
    • Minor: Low-risk procedural or documentation lapses.

5.5 Reporting

  1. Audit Report (Annexure-3) shall be prepared within 5 working days of the audit and submitted to the auditee department and QA Head.
  2. It shall include summary, classification, and suggested corrective actions.

5.6 Corrective and Preventive Actions (CAPA)

  1. Auditee departments must submit CAPA plans (Annexure-4) within 10 working days.
  2. CAPAs must include root cause analysis, corrective measures, and preventive steps.

5.7 Follow-Up and Closure

  1. QA shall verify implementation of CAPAs through:
    • Review of records
    • Follow-up audits if necessary
  2. Closure of each audit shall be recorded in the Audit Closure Log (Annexure-5).

5.8 Documentation and Retention

  1. All audit-related documents shall be retained for a minimum of 5 years.
  2. They must be available for external audits and inspections.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • QA: Quality Assurance
  • NC: Non-Conformance
  • CAPA: Corrective and Preventive Action
  • GMP: Good Manufacturing Practice

7. Documents

  1. Internal Audit Schedule – Annexure-1
  2. Audit Checklist – Annexure-2
  3. Audit Report – Annexure-3
  4. CAPA Form – Annexure-4
  5. Audit Closure Log – Annexure-5

8. References

  • WHO TRS 986 Annex 2 – GMP for Sterile Pharmaceutical Products
  • ICH Q10 – Pharmaceutical Quality System
  • 21 CFR Part 211 – cGMP Regulations

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation QA Executive QA Manager Head QA
Department Quality Assurance Quality Assurance Quality Assurance

11. Annexures

Annexure-1: Internal Audit Schedule

Department Scheduled Date Auditor(s)
Production 15/01/2025 Sunita Reddy
QC 20/01/2025 Rajesh Kumar

Annexure-2: Audit Checklist

Area Audit Point Compliant (Y/N) Remarks
Documentation Batch records updated in real-time Y

Annexure-3: Audit Report

Date Department Auditor Findings Classification
15/01/2025 Production Sunita Reddy Missing calibration record Major

Annexure-4: CAPA Form

Finding Root Cause Corrective Action Preventive Action Responsible
Missing calibration Oversight Recalibrated equipment Monthly log audit Rajesh Kumar

Annexure-5: Audit Closure Log

Audit Date Department Closure Date Verified By
15/01/2025 Production 25/01/2025 QA Manager

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial release New SOP QA Head
24/06/2025 2.0 Updated checklist and annexures Periodic Review QA Head
Exit mobile version